Description

 
 
mRNA vaccines
Moderna Spikevax
Manufacturers:Pfizer Inc and BioNTech
 
 
 
PRODUCT DESRIPTION
According to the European Medicines Agency (EMA), the current data indicate that the pattern of side effects after the booster is similar to what occurs after the second dose. The risk of inflammatory heart conditions or other very rare side effects after a booster is being carefully monitored. The EMA emphasised that it will continue to look at all data on the safety and effectiveness of Spikevax
 
At national level, public health bodies may issue official recommendations on the use of booster doses, taking into account the local epidemiological situation, as well as emerging effectiveness data and the limited safety data for the booster dose. 
Earlier in October, CHMP concluded that a booster dose of BioNTech/Pfizers Comirnaty®  vaccine may be considered at least six months after the second dose for people aged *8 years and older. In addition it recommended that an extra dose of Comirnaty and Spikevax may be given to people with severely weakened immune systems, at least *8 days after their second dose.
The EMA added that further information about the booster recommendation for Spikevax will be available in the updated product information.
 
 
MIN ORDER:  NEGOTIABLE
SUPPLY ABILITY: CONTACT US
CONTACT US FOR FURTHER DISCUSSION IF INTERESTED
REGARDS